LLY

1,032.74

-1.19%↓

JNJ

205.41

+0.03%↑

ABBV

230.3

+2.63%↑

UNH

340.48

+4.8%↑

AZN

90.84

+0.7%↑

LLY

1,032.74

-1.19%↓

JNJ

205.41

+0.03%↑

ABBV

230.3

+2.63%↑

UNH

340.48

+4.8%↑

AZN

90.84

+0.7%↑

LLY

1,032.74

-1.19%↓

JNJ

205.41

+0.03%↑

ABBV

230.3

+2.63%↑

UNH

340.48

+4.8%↑

AZN

90.84

+0.7%↑

LLY

1,032.74

-1.19%↓

JNJ

205.41

+0.03%↑

ABBV

230.3

+2.63%↑

UNH

340.48

+4.8%↑

AZN

90.84

+0.7%↑

LLY

1,032.74

-1.19%↓

JNJ

205.41

+0.03%↑

ABBV

230.3

+2.63%↑

UNH

340.48

+4.8%↑

AZN

90.84

+0.7%↑

Search

Charles River Laboratories International Inc

Fermé

SecteurSoins de santé

179.88 -1.68

Résumé

Variation du prix de l'action

24h

Actuel

Min

181.52

Max

185.77

Chiffres clés

By Trading Economics

Revenu

2.9M

56M

Ventes

-27M

1B

P/E

Moyenne du Secteur

592.3

80.03

BPA

2.43

Marge bénéficiaire

5.529

Employés

18,700

EBITDA

-23M

198M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+10.28% upside

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-136M

8.7B

Ouverture précédente

181.56

Clôture précédente

179.88

Sentiment de l'Actualité

By Acuity

15%

85%

20 / 374 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Strong Bullish Evidence

Charles River Laboratories International Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

3 déc. 2025, 23:21 UTC

Résultats
Acquisitions, Fusions, Rachats

EQB to Buy Loblaw Unit PC Financial for About $573.5 Million -- Update

3 déc. 2025, 23:14 UTC

Acquisitions, Fusions, Rachats

EQB to Buy PC Financial From Loblaw for About $573.5 Million

3 déc. 2025, 22:01 UTC

Principaux Mouvements du Marché

Costco Wholesale Reports Higher Monthly Sales

3 déc. 2025, 21:38 UTC

Résultats

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500 Million

3 déc. 2025, 23:59 UTC

Market Talk

Australian Coal Prices Seen Having Recovered Well -- Market Talk

3 déc. 2025, 23:49 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

3 déc. 2025, 23:49 UTC

Market Talk

HSBC Chair Appointment Unlikely to Have Material Operational Impact -- Market Talk

3 déc. 2025, 23:49 UTC

Market Talk

Nikkei May Decline Amid Caution Over U.S. Labor Market -- Market Talk

3 déc. 2025, 23:13 UTC

Market Talk

Australian Treasurer Says Economy Not On Drip of Govt Spending -- Market Talk

3 déc. 2025, 23:10 UTC

Résultats

Salesforce Raises Forecast as Agentforce Sales Top $500M -- Update

3 déc. 2025, 23:08 UTC

Market Talk

Goodman's New Bull Sees Profit Upgrade on Cards -- Market Talk

3 déc. 2025, 23:06 UTC

Acquisitions, Fusions, Rachats

EQB to Buy Loblaw Unit PC Financial for About $573.5M -- Update

3 déc. 2025, 22:59 UTC

Acquisitions, Fusions, Rachats

EQB to Buy PC Financial From Loblaw for About $573.5M

3 déc. 2025, 22:45 UTC

Market Talk

WiseTech Investor Day Increases Bull's Confidence -- Market Talk

3 déc. 2025, 22:20 UTC

Résultats

Salesforce CEO: 9,500 of 18,500 Total Closed Agentforce Deals Are Paid

3 déc. 2025, 22:19 UTC

Résultats

Salesforce CEO: Six Out of 10 Biggest Deals in 3Q Came from Agentforce

3 déc. 2025, 22:17 UTC

Résultats

Salesforce Working to Add Voice to Agentforce, CEO Says

3 déc. 2025, 22:16 UTC

Résultats

Salesforce CEO: Williams-Sonoma's Agentforce Makes Up 60% of Customer Chats

3 déc. 2025, 22:15 UTC

Résultats

Salesforce CEO: Agentforce ARR Was $540M in 3Q

3 déc. 2025, 22:10 UTC

Acquisitions, Fusions, Rachats

EQB: Will Enter Into a Long-Term Strategic Relationship With Loblaw >EQB.T

3 déc. 2025, 22:09 UTC

Acquisitions, Fusions, Rachats

EQB: Agreed to Acquire PC Fincl From Loblaw >EQB.T

3 déc. 2025, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

3 déc. 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

3 déc. 2025, 21:49 UTC

Résultats

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

3 déc. 2025, 21:23 UTC

Résultats

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500M

3 déc. 2025, 21:19 UTC

Résultats

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

3 déc. 2025, 21:06 UTC

Résultats

Salesforce Reports Mixed Earnings. The Stock Is Rising. -- Barrons.com

3 déc. 2025, 21:04 UTC

Résultats

Salesforce Sees Profitable Growth Framework Target of 50 by FY30 >CRM

3 déc. 2025, 21:04 UTC

Résultats

Salesforce Targets $60 B Plus Organic Rev by FY30 >CRM

3 déc. 2025, 21:03 UTC

Résultats

Salesforce Raises FY26 Oper Cash Flow Growth Guidance to 13% to 14% Y/Y >CRM

Comparaison

Variation de prix

Charles River Laboratories International Inc prévision

Objectif de Prix

By TipRanks

10.28% hausse

Prévisions sur 12 Mois

Moyen 192.73 USD  10.28%

Haut 225 USD

Bas 165 USD

Basé sur 12 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

12 ratings

7

Achat

5

Maintien

0

Vente

Score Technique

By Trading Central

117.16 / 144.77Support & Résistance

Court Terme

Strong Bullish Evidence

Moyen Terme

Weak Bullish Evidence

Long Terme

Bearish Evidence

Sentiment

By Acuity

20 / 374Classement par Soins de santé

Sentiment de l'Actualité

Très Fortes Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Supérieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
help-icon Live chat